Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
- Mechanism
- Curator reviewed · 2 references
Razuprotafib inhibits VE-PTP (https://go.drugbank.com/bio_entities/BE0003769) (a negative regulator of Tie2 in diseased blood vessels) by binding and inhibiting the intracellular catalytic domain of VE-PTP that inactivates Tie2. This in turn allows razuprotafib to restore Tie2 activation to allow for enhancement of endothelial function and stabilization of blood vessels. Razuprotafib is being investigated against diabetic vascular complications and acute respiratory distress syndrome (ARDS) in COVID-19.
- Formula / weight
- C26H26N4O6S3 · 586.7 g/mol (avg)
- Code names
- AKB-9778 · WHO 10271
Resolves to
KWJDHELCGJFUHW-SFTDATJTSA-NSMILESCOC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(NS(O)(=O)=O)C=C1)C1=CSC(=N1)C1=CC=CS1What you can answer from here — as of April 23, 2025
Which drugs share a target with Razuprotafib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account